8XBF

Cryo-EM structure of SARS-CoV-2 S-BQ.1 in complex with antibody O5C2

8XBF の概要

• エントリーDOI: 10.2210/pdb8xbf/pdb
• 関連するPDBエントリー: 8XAL
• EMDBエントリー: 38201 38216
• 分子名称: Spike glycoprotein, O5C2, heavy chain, O5C2, light chain, ... (4 entities in total)
• 機能のキーワード: spike protein, antibody, viral protein
• 由来する生物種: Severe acute respiratory syndrome coronavirus 2; 詳細
• タンパク質・核酸の鎖数: 7
• 化学式量合計: 480193.20

構造登録者

Hsu, H.F.,Wu, M.H.,Chang, Y.C.,Hsu, S.T.D. (登録日: 2023-12-06, 公開日: 2024-06-19, 最終更新日: 2025-06-25)

主引用文献

Chang, Y.H.,Hsu, M.F.,Chen, W.N.,Wu, M.H.,Kong, W.L.,Lu, M.J.,Huang, C.H.,Chang, F.J.,Chang, L.Y.,Tsai, H.Y.,Tung, C.P.,Yu, J.H.,Kuo, Y.,Chou, Y.C.,Bai, L.Y.,Chang, Y.C.,Chen, A.Y.,Chen, C.C.,Chen, Y.H.,Liao, C.C.,Chang, C.S.,Liang, J.J.,Lin, Y.L.,Angata, T.,Hsu, S.D.,Lin, K.I.
Functional and structural investigation of a broadly neutralizing SARS-CoV-2 antibody.
JCI Insight, 9:-, 2024

PubMed Abstract: Since its emergence, SARS-CoV-2 has been continuously evolving, hampering the effectiveness of current vaccines against COVID-19. mAbs can be used to treat patients at risk of severe COVID-19. Thus, the development of broadly protective mAbs and an understanding of the underlying protective mechanisms are of great importance. Here, we isolated mAbs from donors with breakthrough infection with Omicron subvariants using a single-B cell screening platform. We identified a mAb, O5C2, which possesses broad-spectrum neutralization and antibody-dependent cell-mediated cytotoxic activities against SARS-CoV-2 variants, including EG.5.1. Single-particle analysis by cryo-electron microscopy revealed that O5C2 targeted an unusually large epitope within the receptor-binding domain of spike protein that overlapped with the angiotensin-converting enzyme 2 binding interface. Furthermore, O5C2 effectively protected against BA.5 Omicron infection in vivo by mediating changes in transcriptomes enriched in genes involved in apoptosis and interferon responses. Our findings provide insights into the development of pan-protective mAbs against SARS-CoV-2.

PubMed: 38775156
DOI: 10.1172/jci.insight.179726

実験手法

ELECTRON MICROSCOPY (3.6 Å)